View Exam | PowerPak

1. For warfarin-treated patients, the risk of major bleeding increases ____-fold with an INR above 9 compared with patients with INRs in the therapeutic range.

A. 2 B. 4 C. 10 D. 20

2. Which of the following is NOT classified as an ISTH major bleed secondary to anticoagulants?

A. Gastrointestinal bleeding B. A bleed resulting in a 4 g/dL drop in hemoglobin C. Intracranial hemorrhage D. A bleed requiring transfusion of 3 units of packed red blood cells.

3. Reported rates of major bleeding with warfarin in observational real-world studies is ____________ that reported in clinical trials.

A. Higher than B. Lower than C. Similar to D. Double

4. Besides holding the warfarin dose, which of the following is the management strategy recommended in clinical practice guidelines for managing a patient with an INR of 11 who does not have major bleeding?

A. No additional therapy B. Intravenous vitamin K C. Subcutaneous vitamin K D. Oral vitamin K

5. When comparing 3-factor and 4-factor prothrombin complex concentrates (PCCs), 4-factor PCCs contain which clotting factor that is not contained in 3-factor PCCs?

A. Factor II B. Factor VII C. Factor IX D. Factor X

6. In addition to intravenous vitamin K, what dose of 4-factor PCC should be administered to a 110-kg patient who is experiencing an intracranial hemorrhage with an INR of 2.9?

A. 0 (no 4-factor PCC) B. 2500 C. 3500 D. 5000

7. In a patient with an INR of 6.6 experiencing warfarin-associated major bleeding, administration of 4-factor PCCs are expected to bring the INR to less than 1.5 within _______ minutes.

A. 10 B. 30 C. 60 D. 120

8. Prothrombin complex concentrates (PCCs) are preferred over fresh frozen plasma (FFP) for reversal of elevated INRs associated with major warfarin bleeding for all of the following reasons EXCEPT

A. FFP is more expensive than PCCs B. FFP is associated with lung injury C. PCC reverses the INR more rapidly than FFP D. PCCs take less time to administer than FFP

9. Activated prothrombin complex concentrates (aPCCs) are recommended in practice guidelines for reversal of major bleeding associated with

A. Warfarin B. Dabigatran C. Apixaban D. None of the above

10. Which of the following is the best coagulation test to monitor the effectiveness of reversal of major bleeding associated with rivaroxaban?

A. Activated partial thromboplastin time B. Dilute thrombin time C. Prothrombin time D. Drug-specific anti-Xa level

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For warfarin-treated patients, the risk of major bleeding increases ____-fold with an INR above 9 compared with patients with INRs in the therapeutic range.

2. Which of the following is NOT classified as an ISTH major bleed secondary to anticoagulants?

3. Reported rates of major bleeding with warfarin in observational real-world studies is ____________ that reported in clinical trials.

4. Besides holding the warfarin dose, which of the following is the management strategy recommended in clinical practice guidelines for managing a patient with an INR of 11 who does not have major bleeding?

5. When comparing 3-factor and 4-factor prothrombin complex concentrates (PCCs), 4-factor PCCs contain which clotting factor that is not contained in 3-factor PCCs?

6. In addition to intravenous vitamin K, what dose of 4-factor PCC should be administered to a 110-kg patient who is experiencing an intracranial hemorrhage with an INR of 2.9?

7. In a patient with an INR of 6.6 experiencing warfarin-associated major bleeding, administration of 4-factor PCCs are expected to bring the INR to less than 1.5 within _______ minutes.

8. Prothrombin complex concentrates (PCCs) are preferred over fresh frozen plasma (FFP) for reversal of elevated INRs associated with major warfarin bleeding for all of the following reasons EXCEPT

9. Activated prothrombin complex concentrates (aPCCs) are recommended in practice guidelines for reversal of major bleeding associated with

10. Which of the following is the best coagulation test to monitor the effectiveness of reversal of major bleeding associated with rivaroxaban?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For warfarin-treated patients, the risk of major bleeding increases ____-fold with an INR above 9 compared with patients with INRs in the therapeutic range.

2. Which of the following is NOT classified as an ISTH major bleed secondary to anticoagulants?

3. Reported rates of major bleeding with warfarin in observational real-world studies is ____________ that reported in clinical trials.

4. Besides holding the warfarin dose, which of the following is the management strategy recommended in clinical practice guidelines for managing a patient with an INR of 11 who does not have major bleeding?

5. When comparing 3-factor and 4-factor prothrombin complex concentrates (PCCs), 4-factor PCCs contain which clotting factor that is not contained in 3-factor PCCs?

6. In addition to intravenous vitamin K, what dose of 4-factor PCC should be administered to a 110-kg patient who is experiencing an intracranial hemorrhage with an INR of 2.9?

7. In a patient with an INR of 6.6 experiencing warfarin-associated major bleeding, administration of 4-factor PCCs are expected to bring the INR to less than 1.5 within _______ minutes.

8. Prothrombin complex concentrates (PCCs) are preferred over fresh frozen plasma (FFP) for reversal of elevated INRs associated with major warfarin bleeding for all of the following reasons EXCEPT

9. Activated prothrombin complex concentrates (aPCCs) are recommended in practice guidelines for reversal of major bleeding associated with

10. Which of the following is the best coagulation test to monitor the effectiveness of reversal of major bleeding associated with rivaroxaban?

« Return to Activity

Customers who Purchased
this Activity also Purchased